April 1st 2021
The ILLUMINATE-A trial of lumasiran in patients with primary hyperoxaluria type 1 supported the FDA approval of this drug.
September 12th 2012
August 29th 2012
Transdermal system approved for overactive bladder
April 1st 2003Watson Pharma, Inc., has received FDA approval to market oxybutynin transdermal system (Oxytrol) for the treatment of overactive bladder, with symptoms of urge urinary incontinence, urgency, and frequency. A thin patch applied to the abdomen, hip, or buttock twice weekly, it delivers 3.9 mg per day of oxybutynin consistently and continuously through the skin into the bloodstream, according to the company.
Spotlight intensifies on cancer drug reimbursement
April 1st 2003Pharmaceutical manufacturers have long been under scrutiny for the methodsthey employ in marketing their products to physicians. Now, increasing concernthat drug makers are winning physician favor by deeply discounting chemotherapymedicines is placing those physicians under the microscopes of federal andstate authorities.
Antidiuretic found effective in adults with nocturia
March 1st 2003Copenhagen, Denmark-An oral antidiuretic approved for the treatment ofnocturnal enuresis also appears to be effective for treating nocturia inadult men and women, according to phase III clinical trial results reportedby the multinational Nocturia Study Group.
ED therapy found effective in men on antidepressants
March 1st 2003Albuquerque, NM-A recent study by University of New Mexico psychiatristsconfirms what many urologists have observed clinically-that treatment witha PDE-5 inhibitor is effective in men with erectile dysfunction attributableto certain antidepressant medications. The research suggests that effectivetreatment of ED in men with "antidepressant-associated sexual dysfunction"-aparticularly common side effect of serotonin reuptake inhibitors-may improvetheir compliance with these agents.
How to use intravesical chemo post-TUR to treat TCC
March 1st 2003The predictable recurrence of superficial transitional cell carcinoma of the urinary bladder is responsible for the frequent utilization of intravesical therapy. In the past 2 years, we have changed our intravesical treatment strategy at Ohio State University in an effort to enhance efficacy and reduce patient inconvenience.
Estrogen exposure may lead to urethral anomalies
March 1st 2003Boston-Pregnant mice exposed to synthetic estrogens resulted in shorter urethras and disrupted urethral seam closures in their offspring, according to researchers from the University of California, San Francisco. They say their research supports previous cause-and-effect data regarding endocrine disruptors and genital tubercle anomalies.
Oxalate-degrading enzyme reduces stent encrustation
February 1st 2003Italy-Encrustation of urinary tract biomaterial remains a challenging problem for urologists. Devices such as urinary stents and catheters invariably become encrusted with calcium oxalate after long-term placement and are difficult to later remove.
Elevated post-void urine points to high UTI risk
January 1st 2003Chicago-Elevated levels of post-void residual urine appear to be relatedto recurrent urinary tract infection in older women, according to resultsof a retrospective study. In addition, lower post-void residual urine levelsare found in women who take oral estrogen replacement therapy, NorthwesternUniversity urologists report.
Think twice about how you evaluate, treat recurrent UTIs
January 1st 2003Recurrent urinary tract infections are so common in our female patientsthat urologists and other clinicians give little thought to their evaluationand treatment. However, new research findings may lead to some small butimportant changes in our approach to this prevalent urologic problem.
HIPAA's privacy rule: What urologists need to know
January 1st 2003As most urologists know, new federal standards have been established to ensure the privacy of patients' health information as part of the Health Insurance Portability and Accountability Act (HIPAA) of 1996. In my September 2002 article, I presented limited information on HIPAA and its impact on physicians' practices, including the standards for the electronic transmission of health care transactions and the rules associated with implementation.
Oral ED agents: Comparing pharmacologic properties
January 1st 2003Dramatic changes in the management of erectile dysfunction (ED) have occurred since the first FDA-approved oral agent, sildenafil citrate (Viagra), was introduced in 1998. Prior to this time, urologists were the primary source of referral for the diagnosis and treatment of ED.
Once-daily quinolone effective for uncomplicated UTI
January 1st 2003San Diego-A new once-daily formulation of ciprofloxacin (Cipro XR) is equivalent to conventional twice-daily dosing for treatment of uncomplicated urinary tract infections, according to results from a large, multicenter randomized trial. The extended-release formulation was granted FDA approval last month.
A perfect bladder Ca test: We're close but not there yet
December 1st 2002Bladder cancer ranks among the most common human malignancies, with over130,000 newly diagnosed cases each year in the United States and Europeand over 1 million active cases undergoing annual follow-up. Given the traditionaltechnique for diagnosis and monitoring based on passage of a cystoscopeinto the bladder, it is only natural that great efforts are now being focusedtoward finding alternative or confirmatory noninvasive techniques usingurine-based assays.
Verapamil gel found effective in Peyronie's disease
November 1st 2002Orlando, FL-Treatment of Peyronie's disease with verapamil appears to be effective, but the drug's role is still in question and is still being investigated. In research presented at the annual AUA meeting in Orlando, FL, verapamil showed good results when applied as a topical gel, but a second study suggested that the gel does not appear to be absorbed into the tunica albuginea.
New strategies improve success of oral ED therapy
October 1st 2002Orlando, FL-Men with erectile dysfunction who fail initial treatment with sildenafil citrate (Viagra) are seeing varying degrees of improvement when therapy is supplemented with other agents, vacuum devices, or education and counseling.
Renew your interest in ED or lose it to other specialists
October 1st 2002Primary care specialties now account for more than 75% of the prescriptionswritten for sildenafil citrate (Viagra), and this percentage increases almostmonthly. The number of prescriptions written by urologists has remainedstable, and as the erectile dysfunction market increases, urology's percentageof the whole continues to decline. As a specialty, urologists are very busy, and the ratio of patients tophysicians is high. Urology residents who are finishing training have atremendous number of practice opportunities, ranking second only to residentsin dermatology, according to a recent AMA survey. Just look at the numberof classified pages in this issue of Urology Times, which list some of theseopportunities, and compare it with those in an issue of 5 or 10 years ago.
QoL up, costs down with experimental LHRH regimen
October 1st 2002Orlando, FL-Using serum testosterone levels rather than labelguidelines to re-dose patients on luteinizing hormone-releasing hormone(LHRH) agonist depot therapy can substantially reduce treatment costs andimprove a patient's quality of life, according to researchers at Case WesternReserve University, Cleveland.
Combination therapy improves premature ejaculation
October 1st 2002Orlando, FL-Combining sildenafil citrate (Viagra) with a popularantidepressant shows positive results for patients with premature ejaculation,according to results from two separate studies from Israel and Italy. Bothpapers were presented at the AUA annual meeting here.